Mannheimer Swartling has advised BioInvent International in connection with a directed new share issue raising SEK 150 million and broadening the long-term industrial and international institutional ownership in BioInvent.
BioInvent International, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The new shares have been subscribed by DnB NOR Asset Management, the Nordic team and B & E Participation AB, owned by Lars Backsell and Thomas Eldered.
Mannheimer Swartling’s team was led by Madeleine Rydberger, assisted primarily by Per Gruwberger och Jacob Wijkander.